Philip O Buck

ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 7

Top Venues

Human vaccines & immunotherapeutics

Current medical research and opinion

Vaccines

Journal of medical economics

GlaxoSmithKline USA

This page only lists publications with an associated author ORCID identifier.

Affiliation History

GlaxoSmithKline USA

United States

Head, US Health Outcomes and Epidemiology :: Vaccines Medical Affairs

Publications

John Diaz-Decaro, Evan R Myers, Jacek Mucha, Monika Neumann, Witold Lewandowski, Magdalena Kaczanowska, Elvira Schmidt, Andrew Natenshon, Carla Talarico, Philip O Buck
A systematic literature review on the humanistic burden of cytomegalovirus. Current medical research and opinion (2023)
John D Diaz-Decaro, Evan R Myers, Jacek Mucha, Monika Neumann, Witold Lewandowski, Magdalena Kaczanowska, Elvira Schmidt, Andrew Natenshon, Carla Talarico, Philip O Buck
A systematic literature review of the economic and healthcare resource burden of cytomegalovirus. Current medical research and opinion (2023)
Tinevimbo Shiri, Marc Evans, Carla A Talarico, Angharad R Morgan, Maaz Mussad, Philip O Buck, Phil McEwan, William David Strain
The Population-Wide Risk-Benefit Profile of Extending the Primary COVID-19 Vaccine Course Compared with an mRNA Booster Dose Program. Vaccines 10 (2) (2022)
Oscar Herrera-Restrepo, Kimberly Davis, Carolyn Sweeney, Eric Davenport, Parinaz K Ghaswalla, Philip O Buck
Hepatitis A and B vaccination in adults at risk: A survey of US healthcare providers' attitudes and practices. Human vaccines & immunotherapeutics (2022)
Michele A Kohli, Michael Maschio, Amy Lee, Kelly Fust, Nicolas Van de Velde, Philip O Buck, Milton C Weinstein
The potential clinical impact of implementing different COVID-19 boosters in fall 2022 in the United States. Journal of medical economics 25 (1) (2022)
Brandon J Patterson, Chi-Chang Chen, Catherine B McGuiness, Lisa I Glasser, Kainan Sun, Philip O Buck
Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019. Human vaccines & immunotherapeutics 17 (8) (2021)
Amber Hsiao, Philip O Buck, Arnold Yee, John Hansen, Edwin M Lewis, Laurie L Aukes, Emad Yanni, Rafik Bekkat-Berkani, Anne E Schuind, Nicola P Klein
Retrospective study of the use of an influenza disease two-tiered classification system to characterize clinical severity in US children. Human vaccines & immunotherapeutics 16 (8) (2020)

Philip O Buck.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Philip O Buck